|5.77||-0.0700||-1.20%||Vol 5.88M||1Y Perf -19.37%|
|Jun 15th, 2021 16:00 DELAYED|
|- -||0.03 0.52%|
|Target Price||6.69||Analyst Rating||Hold 3.14|
|Potential %||15.94||Finscreener Ranking||★★★+ — -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||603.34M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||24.07||Earnings Date||5th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th Aug 2021|
|Estimated EPS Next Report||-0.57|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||16.11M|
|Avg. Monthly Volume||8.16M|
|Avg. Quarterly Volume||11.32M|
Clovis Oncology Inc. (NASDAQ: CLVS) stock closed at 5.77 per share at the end of the most recent trading day (a -1.2% change compared to the prior day closing price) with a volume of 5.92M shares and market capitalization of 603.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Clovis Oncology Inc. CEO is Patrick J. Mahaffy.
The one-year performance of Clovis Oncology Inc. stock is -19.37%, while year-to-date (YTD) performance is 20.21%. CLVS stock has a five-year performance of -58.1%. Its 52-week range is between 4.08 and 11.1, which gives CLVS stock a 52-week price range ratio of 24.07%
Clovis Oncology Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 7.70, a price-to-sale (PS) ratio of 3.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.55%, a ROC of -18.45% and a ROE of 188.78%. The company’s profit margin is -%, its EBITDA margin is -189.20%, and its revenue ttm is $160.01 Million , which makes it $1.53 revenue per share.
Of the last four earnings reports from Clovis Oncology Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Clovis Oncology Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for Clovis Oncology Inc. is Hold (3.14), with a target price of $6.69, which is +15.94% compared to the current price. The earnings rating for Clovis Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Clovis Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Clovis Oncology Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.05, ATR14 : 0.43, CCI20 : 81.89, Chaikin Money Flow : -0.44, MACD : 0.05, Money Flow Index : 68.62, ROC : 10.54, RSI : 52.70, STOCH (14,3) : 34.08, STOCH RSI : 0.26, UO : 38.21, Williams %R : -65.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Clovis Oncology Inc. in the last 12-months were: Brian G. Atwood (Option Excercise at a value of $21 240), Daniel W. Muehl (Option Excercise at a value of $0), Daniel W. Muehl (Sold 23 339 shares of value $157 380 ), Gillian C. Ivers-Read (Option Excercise at a value of $226 205), Gillian C. Ivers-Read (Sold 22 511 shares of value $153 154 ), Lindsey Rolfe (Option Excercise at a value of $56 550), Lindsey Rolfe (Sold 27 286 shares of value $183 940 ), Paul Edward Gross (Option Excercise at a value of $0), Paul Edward Gross (Sold 23 099 shares of value $156 167 ), Thomas C. Harding (Option Excercise at a value of $0), Thomas C. Harding (Sold 17 828 shares of value $118 098 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.